Alert detail
FDA Approval: ROMVIMZA (VIMSELTINIB) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA219304Specialty: OncologyAdded: 7/1/2026Effective: 2025-02-14federal register
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.